Victoria has further cemented its position as a leading hub for life sciences innovation with BioNTech’s Clinical Trial Platform developed in partnership with the Peter MacCallum Cancer Centre.
The platform supports the development of investigational therapies for hard-to-treat cancers. BioNTech has entered into an agreement with the Peter MacCallum Cancer Centre to establish the platform, creating a network of key delivery partners including Austin Health, Alfred Health and Monash Health.
This agreement highlights the commercial and collaboration opportunities for biotech and life sciences companies seeking to develop and deliver innovative therapies within Victoria’s thriving biomedical ecosystem.
By harnessing the strength of Victoria’s life sciences sector, we aim to streamline clinical trials and expedite the development of innovative investigational treatments for people with cancer.
David Sparling – Site Head Australia, BioNTech
The platform is designed to streamline clinical trials through efficient data collection, planning and patient access. Its objective is to improve access for cancer patients to BioNTech’s innovative clinical trials across Australia, giving them more investigational treatment options.
BioNTech is working with internationally renowned principal investigators and clinical trial teams from hospitals across Melbourne, regional Victoria and Australia to offer investigational targeted treatments for lung, breast, melanoma, head and neck cancers and other common cancers – with more to come.
The platform has started its first clinical trial for an investigational breast cancer treatment at the Peter MacCallum Cancer Centre. The trial is evaluating the safety and efficacy of immunotherapy administered in combination with chemotherapy for participants with triple-negative breast cancer.
As part of the strategic partnership with mRNA Victoria, BioNTech is establishing a state-of-the-art mRNA manufacturing facility at La Trobe University’s Bundoora campus to support research and development and clinical-scale manufacturing of investigational mRNA-based medicines.
This forms part of the Government’s broader investment to position Victoria as a global destination for biotechnology and ensures we remain at the forefront of mRNA innovation.
Victoria is the only place in the world where both mRNA global leaders – Moderna and BioNTech – have chosen to establish research and development and manufacturing operations.
The Government invested $5 million to drive growth in clinical trials and enable industry-sponsored clinical trials across our state.
Victoria’s world-leading research facilities and ongoing government investment in the local life sciences sector including the Melbourne Biomedical Precinct, foster a competitive environment for collaboration and innovation.
The Victorian Government has also invested more than $1 billion towards health and medical research over the past decade – driving growth in the sector, creating jobs and supporting incredible breakthroughs in treatment and care.
Unlock partnership opportunities through Victoria’s dynamic medical research industry
